

## ALPHA COGNITION ANNOUNCES ENGAGEMENT OF INVESTOR RELATIONS SERVICE PROVIDER

Vancouver, BC – December 15, 2023 – Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce that it has entered into an agreement with Planet Ventures Inc. (“Planet”) dated December 13<sup>th</sup>, 2023 (the “Agreement”) for the provision of investor relations and communication services to the Company.

Pursuant to the terms and conditions of the Agreement, Planet has agreed to provide the Company with public relations and marketing services, among other things, in an effort to increase public awareness of the Company. The services may be delivered in a variety of mediums through different platforms, including, but not limited to social media and industry-related platforms. The Agreement is for a term commencing on December 20, 2023, and expiring on December 30, 2024. In accordance with the terms and conditions of the Agreement and as consideration for its services, the Company will pay Planet a one-time cash fee of CAD\$160,000.

Planet is a Vancouver-based investment issuer that trades on the TSX Venture Exchange under the symbol “PXI”. In addition to its wholly owned subsidiaries and investment portfolio, Planet assists micro-, small- and mid-cap public companies with market awareness campaigns; it helps them gain valued industry exposure through its large network of licensed advisers and institutional investors. Planet operates as an arm’s length service provider to the Company and is not entitled to receive any securities of the Company in connection with this engagement. Planet’s business is located at Suite 303, 750 West Pender Street, Vancouver, British Columbia, V6C 2T7 and Planet can be contacted at: [info@planetventuresinc.com](mailto:info@planetventuresinc.com) and 604 681 0084.

### About Alpha Cognition Inc.

Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.

ALPHA-1062, is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ALPHA-1062’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the



alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.

**For further information:**

Michael McFadden, CEO  
Tel: 1-858-344-4375  
[info@alphacognition.com](mailto:info@alphacognition.com)  
<https://www.alphacognition.com>

*Forward-looking Statements*

*Certain information contained herein constitutes "forward-looking information" under Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to Planet's services and term of engagement. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "will" or variations of such words and phrases or statements that certain actions, events or results "will" occur. Such forward looking statements include statements regarding the potential benefits of ALPHA-1062. Such statements, and other forward-looking statements herein, are based on the opinions and estimates of management as of the date such statements are made and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.*